Actavis plan to switch Namenda drug was unlawful, says US court

01-06-2015

A US appeals court has ruled that Actavis’s attempt to force Alzheimer’s patients to switch from one medication to another before generic companies entered the market was anti-competitive.


US Court of Appeals for the Second Circuit, Namenda, product hopping, Actavis, Eric Schneiderman, patent

LSIPR